Sidra Medicine Completes Qatar’s First Pediatric Allogeneic Stem Cell Transplant

Sidra Medicine Completes Qatar’s First Pediatric Allogeneic Stem Cell Transplant

Doha – Sidra Medicine has successfully performed Qatar’s first pediatric allogeneic hematopoietic stem cell transplantation (HSCT), a procedure that marks a major advancement in treating complex childhood cancers and blood disorders locally.

The transplant took place on a nine-year-old boy diagnosed with relapsed acute lymphoblastic leukemia (ALL), a common form of childhood cancer. He received stem cells donated by his brother, making this an allogeneic procedure where donor cells replace the patient’s damaged bone marrow.

The boy’s treatment at Sidra Medicine started in 2019 with a diagnosis of ALL. He underwent standard chemotherapy for two years, achieving initial remission. However, relapses occurred in May 2022 and again in December 2024. At that point, the medical team concluded that an allogeneic HSCT provided the strongest opportunity for long-term recovery. Without this intervention, options for children with relapsed ALL are limited, and outcomes are often poor.

This successful transplant builds on the opening of Sidra Medicine’s dedicated HSCT ward in June 2025. The ward, inaugurated by Her Highness Sheikha Moza bint Nasser, features specialized isolation rooms and advanced facilities designed for pediatric patients. It initially focused on autologous transplants—using the patient’s own cells—but has now expanded to allogeneic procedures.

Dr. Ahmed Al Hammadi, Chair of Pediatric Medicine at Sidra Medicine, described the achievement as a key step forward. “This first pediatric allogeneic stem cell transplant strengthens our ability to offer advanced cellular therapies here in Qatar,” he said. “It means children can receive this specialized care close to their families, without needing to travel abroad.”

Dr. Chiara Cugno, Acting Chief of Pediatric Hematology, Oncology and HSCT, and Director of the Advanced Cell Therapy Core, highlighted the team’s expertise. “Our program now serves both local and international patients,” she noted. “With more than 50 children in Qatar currently awaiting transplantation, this capability addresses a real national need.”

The procedure involved close coordination between clinical teams and laboratory staff. Stem cells from the donor brother were processed in Sidra’s on-site facilities, ensuring high standards of safety and quality. Post-transplant, the patient will receive ongoing monitoring and support, including regular check-ups during the critical first year.

Sidra Medicine’s HSCT program developed through partnerships, including collaboration with Children’s Hospital of Philadelphia for training and protocols. The hospital is the only facility in Qatar providing comprehensive pediatric hematology and oncology care, handling 70 to 100 new childhood cancer cases annually.

This milestone reduces the need for families to seek treatment overseas. Previously, many complex cases required international referrals, but local advancements like this transplant are changing that. Two additional pediatric patients are already under care in the HSCT program.

Photo credit: Sidra Medicine

Share: